Beijing Xiehe Bioengineering United Company

Dementia is a growing global public health concern currently affecting 50 million people and is expected to rise dramatically to more than 150 million cases worldwide by 2050. Obesity, commonly measured by body mass index (BMI), continues to be a global epidemic and earlier studies suggested that obesity at midlife may lead to increased risk for dementia. But the association between BMI and the risk of dementia remains unclear. Now, researchers have found that different patterns of BMI changes over one's life course may be an indicator of a person's risk for dementia. Dementia is a growing global public health concern currently affecting 50 million people and is expected to rise dramatically to more than 150 million cases worldwide by 2050. Obesity, commonly measured by body mass index (BMI), continues to be a global epidemic and earlier studies suggested that obesity at midlife may lead to increased risk for dementia. But the association between BMI and the risk of dementia remains unclear. Now, researchers from Boston University Chobanian & Avedisian School of Medicine and Chinese Academy of Medical Sciences & Peking Union Medical College, have found that different patterns of BMI changes over one's life course may be an indicator of a person's risk for dementia. "These findings are important because previous studies that looked at weight trajectories didn't consider how patterns of weight gain/stability/loss might help signal that dementia is potentially imminent," explained corresponding author Rhoda Au, PhD, professor of anatomy and neurobiology. Through the Framingham Heart Study, a group of participants was followed for 39 years and their weight was measured approximately every 2-4 years. The researchers compared different weight patterns (stable, gain, loss) among those who did and did not become demented. They found the overall trend of declining BMI was associated with a higher risk of developing dementia. However, after further exploration, they found a subgroup with a pattern of initial increasing BMI followed by declining BMI, both occurring within midlife, which appeared to be central to the declining BMI-dementia association. Au points out that for individuals, family members, and primary care physicians, it is relatively easy to monitor weight. "If after a steady increase in weight that is common as one gets older, there is an unexpected shift to losing weight post midlife, it might be good to consult with one's healthcare provider and pinpoint why. There are some potential treatments emerging where early detection might be critical in the effectiveness of any of these treatments as they are approved and become available," she adds. The researchers hope this study will illustrate that the seeds for dementia risk are being sowed across many years, likely even across the entire lifespan. "Dementia is not necessarily inevitable and monitoring risk indicators such as something as easy to notice as weight patterns, might offer opportunities for early intervention that can change the trajectory of disease onset and progression." These findings appear online in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Funding for this study was provided by the Non-profit Central Research Institute Fund of Chinese Academic of Medical Science (2021-JKCS-023), the Framingham Heart Study's National Heart, Lung, and Blood Institute contract (N01-HC-25195), the National Institute on Aging (AG016495, AG008122, AG033040, AG062109, AG049810, AG054156, AG062109, AG068753), National Institute of Neurological Disorders and Stroke (R01-NS017950) and VMF-14-318524 from the Alzheimer's Association and Pfizer.

ROCKVILLE, Md. and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), olverembatinib (BCL-ABL TIK), IBI188(anti-CD47 monoclonal antibody), IBI110 (anti-LAG-3 monoclonal antibody) and IBI939 (anti-TIGIT monoclonal antibody) will be presented at the upcoming international medical conferences. A brief summary of the presentations is as follows: EUROPEAN SOCIETY OF MEDICAL ONCOLOGY IMMUNO-ONCOLOGY CONGRESS 2022 (Dec 7-9) Topic: Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in advanced squamous non-small cell lung cancer (sqNSCLC): updated results of the Phase Ib study Presentation Type: Poster Poster Number: 86P Main Researchers: Professor Caicun Zhou, Shanghai Pulmonary Hospital; Professor Nong Xu, The First Affiliated Hospital, School of Medicine, Zhejiang University. Topic: A Study to Evaluate the Safety, Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Presentation Type: Poster Poster Number: 77P Main Researcher: Professor Ying Cheng, Jilin Cancer Hospital. 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING & EXPOSITION (Dec 10-13) Topic: A phase 1b study to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome Presentation Type: Poster Poster Number: 1759 Main Researchers: Professor Zhijian Xiao, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Professor Miao Miao, The First Affiliated Hospital of Suzhou University. Topic: Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation Presentation Type: Oral Presentation Abstract Number: 170698 Main Researcher: Professor Qian Jiang, Peking University Institute of Hematology, Peking University People's Hospital. Topic: A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI）, in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China with T315I Mutation Presentation Type: Oral Presentation Abstract Number: 170868 Main Researcher: Professor Qian Jiang, Peking University Institute of Hematology, Peking University People's Hospital. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune disease, metabolic disorder and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK. Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 35 valuable assets in the fields of cancer, metabolic disorder, autoimmune disease and other major therapeutic areas, with 8 approved products on the market. These include: TYVYT® (sintilimab injection), BYVASDA®(bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA®(rituximab biosimilar injection), Pemazyre®(pemigatinib oral inhibitor), olverembatinib (BCR-ABL TKI), Cyramza® (ramucirumab) and selpercatinib. An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies. Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. Innovent strives to work with many collaborators to help advance China's biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. For more information, please visit: . and . Note: TYVYT® (sintilimab injection) is not an approved product in the United States. BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States. TYVYT® (sintilimab injection, Innovent) BYVASDA® (bevacizumab biosimilar injection, Innovent) HALPRYZA® (rituximab biosimilar injection, Innovent) SULINNO® (adalimumab biosimilar injection, Innovent) Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan. CYRAMZA® (ramucirumab, Eli Lilly). CYRAMZA® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Selpercatinib (Eli Lilly). Selpercatinib was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Disclaimer: 1. The indications are still under clinical study, which haven't been approved in China. 2. Innovent does not recommend any off-label usage. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. SOURCE Innovent Biologics

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it will present preliminary safety and efficacy results for ET-01, its investigational gene-editing therapy for transfusion dependent β-thalassemia (TDT) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, Louisiana. It is reported to be approximately 15,000 to 30,000 patients with β-Thalassemia Major (β-TM) in China. A recent cross-sectional survey initiated by the Institute of Hematology & Blood Diseases Hospital found that only 7% of the samplings are expected to live beyond age 18. The presentation highlights data from an investigator initiated trial of ET-01 performed at the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College involving one subject with TDT. The study demonstrated that a single dose of ET-01 consisting of gene-edited autologous CRISPR/Cas9 mediated CD34+ cells resulted in timely engraftment, a significant and durable increase in the level of fetal hemoglobin production, and achieved transfusion independence for 15 months since three months after ET-01 infusion at the time of data cut-off by May 20, 2022. The safety pro ET-01 was consistent with that of autologous hematopoietic stem cell transplantation and myeloablative conditioning. These preliminary data support further testing of ET-01 treatment for patients with TDT. “I am glad to see that the patient, who needed a transfusion of red blood cells every two weeks, has been transfusion free since February 2021. We are conducting additional research to further elucidate how gene-edited hematopoietic stem cells engraft and differentiate, hoping to shed light on the implication of gene editing in the short and long term,” said Dr. Jun Shi, Director of the Regenerative Medicine Clinic at the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College and the first presenter of the study. “These data preliminarily validate ET-01’s safety pro its robust and potentially lasting clinical benefits to patients," said Dong Wei, Ph.D., CEO of EdiGene. “Leveraging our expertise in gene editing and in-depth knowledge in the field of hematopoietic stem cells, we’re working to advance the development of ET-01 with the hope of bringing the potential one-time cure for patients with transfusion dependent β-thalassemia.” ET-01 is currently in a multi-center Phase I clinical trial in China, with subjects’ enrollment completed earlier this year. Details of the presentation Title: Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia Publication Number: 4778 Session Name: 801. Gene Therapies: Poster III Session Date and Time: Monday, December 12, 2022, 6:00 PM - 8:00 PM (ET) Location: Ernest N. Morial Convention Center, Hall D Presenter: Dr. Jun Shi, Director of the Regenerative Medicine Clinic at the Institute of Hematology & Blood Diseases Hospital of the Chinese Academy of Medical Sciences & Peking Union Medical College About ET-01 ET-01 is an autologous CD34+ hematopoietic stem/progenitor cells with the erythroid-specific enhancer of the BCL11A gene modified by CRISPR/Cas9. ET-01 is the first gene-editing experimental therapy and the first hematopoietic stem cell experimental therapy with IND application approval by China National Medical Products Administration (NMPA). About EdiGene, Inc. EdiGene Inc. is a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER™-based in vivo RNA base editing, ex vivo gene-editing hematopoietic stem cells, and ex vivo gene-editing T cells for allogeneic CAR-T. Founded in 2015, EdiGene is headquartered in Beijing, with offices in Guangzhou and Shanghai, China, and Cambridge, Massachusetts, USA. More information can be found at View source version on businesswire.com: Contacts Xiaomeng Zhang EdiGene, Inc. +86 10-80733899 media@edigene.com Source: EdiGene, Inc. View this news release online at: